X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-08-18 | HUMA | Humacyte, Inc. | Dougan Brady W | Dir | S - Sale | $1.67 | -2,241,045 | 1,392,091 | -62% | -$3,733,191 | |||||
| M | 2025-08-18 | HUMA | Humacyte, Inc. | Niklason Laura E | Pres, CEO, Dir | S - Sale | $1.67 | -2,241,045 | 1,392,091 | -62% | -$3,733,191 | |||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | Chief Technical Officer | S - Sale | $4.67 | -2,848 | 60,372 | -5% | -$13,294 | ||||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Robertson Jenny | GC | S - Sale | $4.67 | -542 | 62,556 | -1% | -$2,530 | ||||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Adler Eric | Chief Medical Officer | S - Sale | $4.67 | -608 | 67,073 | -1% | -$2,838 | ||||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $4.67 | -2,735 | 220,058 | -1% | -$12,767 | ||||||
2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | See Tai Sandi | Chief Development Officer | S - Sale | $4.67 | -382 | 58,860 | -1% | -$1,783 | ||||||
2025-08-18 | ACOG | Alpha Cognition Inc. | Mertz Phillip Joseph | Dir | S - Sale | $9.00 | -27,778 | 35,022 | -44% | -$250,002 | ||||||
2025-08-18 | ATRA | Atara Biotherapeutics, Inc. | Nguyen Anhco | Pres, CEO | S - Sale | $11.62 | -2,958 | 67,889 | -4% | -$34,360 | ||||||
2025-08-18 | ATRA | Atara Biotherapeutics, Inc. | Grant-Huerta Yanina | Chief Accounting Officer | S - Sale | $11.61 | -1,809 | 35,258 | -5% | -$21,009 | ||||||
2025-08-18 | ACOG | Alpha Cognition Inc. | Mertz Leonard Powell | Dir | P - Purchase | $9.00 | +27,778 | 259,998 | +12% | +$250,002 | ||||||
2025-08-18 | VYGR | Voyager Therapeutics, Inc. | Ferguson Toby | Chief Medical Officer | S - Sale | $3.73 | -19,000 | 138,914 | -12% | -$70,870 | ||||||
| DM | 2025-08-18 | IVVD | Invivyd, Inc. | Lee Timothy Edward | Chief Commercial Officer | S - Sale+OE | $0.60 | -49,656 | 59,344 | -46% | -$29,808 | |||||
| DM | 2025-08-18 | IVVD | Invivyd, Inc. | Duke William E. | CFO | S - Sale+OE | $0.60 | -49,656 | 49,344 | -50% | -$29,808 | |||||
| DM | 2025-08-18 | IVVD | Invivyd, Inc. | Green Julie | CHRO | S - Sale+OE | $0.60 | -49,656 | 49,344 | -50% | -$29,808 | |||||
| DM | 2025-08-18 | IVVD | Invivyd, Inc. | Andersen Jill | GC, Secretary | S - Sale+OE | $0.60 | -82,754 | 84,946 | -49% | -$49,677 | |||||
| DM | 2025-08-18 | IVVD | Invivyd, Inc. | Allen Robert D. III | Chief Scientific Officer | S - Sale+OE | $0.60 | -45,932 | 53,068 | -46% | -$27,573 | |||||
2025-08-15 | REPL | Replimune Group, Inc. | Hill Emily Luisa | CFO | S - Sale | $5.37 | -9,154 | 134,368 | -6% | -$49,157 | ||||||
2025-08-15 | ATRA | Atara Biotherapeutics, Inc. | Panacea Innovation Ltd | 10% | P - Purchase | $12.19 | +55,000 | 1,405,000 | +4% | +$670,423 | ||||||
| M | 2025-08-15 | ADAP | Adaptimmune Therapeutics Plc | Behbahani Ali | Dir | S - Sale | $0.01 | -19,500,000 | 0 | -100% | -$229,172 | |||||
2025-08-18 | RXRX | Recursion Pharmaceuticals, Inc. | Khan Najat | Chief R, D Commercial Officer | S - Sale | $5.52 | -36,599 | 668,197 | -5% | -$202,173 | ||||||
| M | 2025-08-15 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $39.34 | -260,713 | 3,205,260 | -8% | -$10,255,244 | |||||
2025-08-18 | SRRK | Scholar Rock Holding Corp | Parlavecchio Caryn | CHRO | S - Sale | $31.17 | -2,178 | 155,464 | -1% | -$67,880 | ||||||
| D | 2025-08-18 | CRSP | Crispr Therapeutics AG | Kulkarni Samarth | CEO | S - Sale+OE | $58.15 | -13,081 | 292,626 | -4% | -$760,660 | |||||
| M | 2025-07-17 | VXRT | Vaxart, Inc. | Finney Kevin | Dir | P - Purchase | $0.37 | +166,668 | 204,771 | +437% | +$61,934 | |||||
2025-08-18 | TNYA | Tenaya Therapeutics, Inc. | Higa Tomohiro | SVP, Finance | S - Sale | $1.25 | -2,962 | 95,338 | -3% | -$3,711 | ||||||
2025-08-18 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Chief Medical Officer | S - Sale | $1.25 | -5,053 | 172,803 | -3% | -$6,331 | ||||||
2025-08-18 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | CEO | S - Sale | $1.25 | -14,533 | 302,792 | -5% | -$18,210 | ||||||
| D | 2025-08-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale+OE | $118.53 | -28,000 | 114,168 | -20% | -$3,318,927 | |||||
2025-08-15 | ARTV | Artiva Biotherapeutics, Inc. | Aslan Fred | Pres, CEO | S - Sale | $2.73 | -25,500 | 382,221 | -6% | -$69,579 | ||||||
2025-08-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $118.53 | -2,500 | 160,110 | -2% | -$296,325 | ||||||
| D | 2025-08-18 | AURA | Aura Biosciences, Inc. | Elazzouzi Amy | SVP, Finance | S - Sale+OE | $6.70 | -7,722 | 86,558 | -8% | -$51,737 | |||||
| D | 2025-08-15 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $16.88 | -21,000 | 3,756,233 | -1% | -$354,480 | |||||
| D | 2025-08-13 | BCRX | Biocryst Pharmaceuticals Inc | Heggie Theresa | Dir | S - Sale+OE | $8.51 | -70,000 | 65,352 | -52% | -$595,868 | |||||
2025-08-12 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COFO, Secretary | S - Sale | $13.58 | -2,937 | 766,095 | 0% | -$39,884 | ||||||
| M | 2025-08-12 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale | $13.81 | -3,743 | 424,804 | -1% | -$51,684 | |||||
| D | 2025-08-11 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $5.28 | -618,175 | 994,619 | -38% | -$3,263,964 | |||||
2025-08-13 | MXCT | Maxcyte, Inc. | Douglas Richard | Dir | P - Purchase | $1.39 | +80,000 | 230,577 | +53% | +$111,040 | ||||||
2025-08-13 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.83 | +100 | 168,062 | 0% | +$183 | ||||||
| DM | 2025-08-11 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $63.62 | -60,000 | 733,719 | -8% | -$3,817,389 | |||||
2025-08-11 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $50.00 | -6,000 | 871,741 | -1% | -$300,000 | ||||||
2025-08-12 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.75 | +400 | 167,962 | 0% | +$700 | ||||||
2025-06-10 | PLX | Protalix Biotherapeutics, Inc. | Schwartz Aharon | Dir | P - Purchase | $1.60 | +129,000 | 303,000 | +74% | +$205,884 | ||||||
2025-08-08 | RGEN | Repligen Corp | Madaus Martin D | Dir | P - Purchase | $112.13 | +1,800 | 7,397 | +32% | +$201,830 | ||||||
2025-08-11 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.76 | +1,700 | 167,562 | +1% | +$2,989 | ||||||
| D | 2025-08-07 | NBIX | Neurocrine Biosciences Inc | Gorman Kevin Charles | Dir | S - Sale+OE | $126.41 | -106,322 | 514,596 | -17% | -$13,440,281 | |||||
2025-08-06 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $37.78 | -2,725 | 236,273 | -1% | -$102,951 | ||||||
2025-08-07 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $2.58 | -679 | 16,827 | -4% | -$1,752 | ||||||
2025-08-06 | CRSP | Crispr Therapeutics AG | Treco Douglas A | Dir | P - Purchase | $57.03 | +20,000 | 22,000 | >999% | +$1,140,600 | ||||||
| D | 2025-08-06 | VCEL | Vericel Corp | McLaughlin Kevin F | Dir | S - Sale+OE | $35.92 | -7,000 | 15,100 | -32% | -$251,440 | |||||
2025-08-04 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $0.53 | -296 | 405,686 | 0% | -$158 | ||||||
2025-08-04 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $28.36 | -186 | 49,780 | 0% | -$5,276 | ||||||
| D | 2025-08-04 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $28.36 | -5,585 | 639,721 | -1% | -$158,413 | |||||
2025-08-04 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $28.36 | -1,255 | 126,206 | -1% | -$35,597 | ||||||
2025-08-04 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $28.36 | -785 | 103,827 | -1% | -$22,266 | ||||||
2025-08-04 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $28.36 | -3,189 | 235,153 | -1% | -$90,453 | ||||||
2025-08-05 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $8.09 | -10,000 | 55,878 | -15% | -$80,900 | ||||||
2025-08-01 | DYAI | Dyadic International Inc | Hazelton Joseph P | Pres, COO | P - Purchase | $0.95 | +26,000 | 155,340 | +20% | +$24,700 | ||||||
2025-08-04 | FATE | Fate Therapeutics Inc | Tahl Cindy | See Remarks | S - Sale | $1.06 | -9,037 | 397,670 | -2% | -$9,573 | ||||||
2025-08-04 | FATE | Fate Therapeutics Inc | Valamehr Bahram | Pres, CEO | S - Sale | $1.06 | -14,466 | 334,898 | -4% | -$15,396 | ||||||
2025-07-31 | ABP | Abpro Holdings, Inc. | Suk Jin Wook (Miles) | CEO, COB | P - Purchase | $0.28 | +72,035 | 718,512 | +11% | +$20,170 | ||||||
2025-07-31 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $2.49 | -5,121 | 64,398 | -7% | -$12,757 | ||||||
2025-08-01 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $4.99 | -22,000 | 1,276,391 | -2% | -$109,699 | ||||||
2025-08-01 | PRME | Prime Medicine, Inc. | Nelsen Robert | Dir, 10% | P - Purchase | $3.30 | +3,030,300 | 18,502,974 | +20% | +$9,999,990 | ||||||
2025-08-01 | PRME | Prime Medicine, Inc. | Arch Venture Partners Xii, LLC | 10% | P - Purchase | $3.30 | +3,030,300 | 18,486,894 | +20% | +$9,999,990 | ||||||
2025-08-01 | PRME | Prime Medicine, Inc. | Arch Venture Partners X, LLC | 10% | P - Purchase | $3.30 | +3,030,300 | 18,486,894 | +20% | +$9,999,990 | ||||||
2025-07-30 | BEAM | Beam Therapeutics Inc. | Fmr LLC | See Remark 1, 10% | S - Sale | $20.50 | -48,374 | 3,213,581 | -1% | -$991,667 | ||||||
2025-07-29 | VXRT | Vaxart, Inc. | Watson W. Mark | Dir | P - Purchase | $0.41 | +10,000 | 104,125 | +11% | +$4,050 | ||||||
2025-07-29 | DBVT | Dbv Technologies S.A. | Mohideen Pharis | Chief Medical Officer | S - Sale | $2.22 | -464 | 109,649 | 0% | -$1,030 | ||||||
2025-07-30 | CRDF | Cardiff Oncology, Inc. | Pace Gary W | Dir | P - Purchase | $2.45 | +290,000 | 2,676,352 | +12% | +$710,500 | ||||||
| M | 2025-07-28 | ADAP | Adaptimmune Therapeutics Plc | Ecor1 Capital, LLC | 10% | S - Sale | $0.11 | -64,052,538 | 100,371,882 | -39% | -$6,890,236 | |||||
| M | 2025-07-28 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $3.68 | -17,083 | 377,998 | -4% | -$62,947 | |||||
| M | 2025-07-28 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $3.69 | -20,081 | 335,295 | -6% | -$74,000 | |||||
| M | 2025-07-28 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $3.69 | -30,770 | 552,720 | -5% | -$113,478 | |||||
| M | 2025-07-28 | RLAY | Relay Therapeutics, Inc. | Adams Brian | GC | S - Sale | $3.68 | -19,913 | 371,472 | -5% | -$73,378 | |||||
| D | 2025-07-25 | IMA | Imagenebio, Inc. | Bonita David P | Dir | P - Purchase | $29.90 | +83,611 | 774,133 | +12% | +$2,499,969 | |||||
| D | 2025-07-25 | IMA | Imagenebio, Inc. | Stampacchia Otello | Dir | P - Purchase | $29.90 | +267,556 | 455,361 | +142% | +$7,999,924 | |||||
| D | 2025-07-28 | CADL | Candel Therapeutics, Inc. | Nichols William Garrett | Chief Medical Officer | S - Sale+OE | $6.98 | -937 | 52,493 | -2% | -$6,540 | |||||
2025-07-28 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $113.94 | -10,000 | 605,725 | -2% | -$1,139,370 | ||||||
2025-07-25 | CVM | Cel Sci Corp | Watson Robert Eugene | Dir | P - Purchase | $6.85 | +2,919 | 3,733 | +359% | +$19,995 | ||||||
2025-07-25 | CVM | Cel Sci Corp | Kersten Geert R | CEO | P - Purchase | $6.85 | +29,197 | 72,835 | +67% | +$199,999 | ||||||
2025-07-23 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $18.15 | -2,805 | 204,919 | -1% | -$50,911 | ||||||
2025-07-23 | IMVT | Immunovant, Inc. | Geffner Michael | Chief Medical Officer | S - Sale | $18.15 | -2,385 | 221,825 | -1% | -$43,288 | ||||||
2025-07-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $35.74 | -2,232 | 238,342 | -1% | -$79,774 | ||||||
| M | 2025-07-22 | PASG | Passage Bio, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $5.70 | +128,848 | 1,067,667 | +14% | +$733,826 | |||||
2025-07-22 | MGTX | Meiragtx Holdings Plc | Giroux Richard | CFO, COO | S - Sale | $8.52 | -24,000 | 943,646 | -2% | -$204,480 | ||||||
| D | 2025-07-17 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $9.84 | -1,084 | 10,679 | -9% | -$10,669 | |||||
2025-07-17 | ATRA | Atara Biotherapeutics, Inc. | Panacea Innovation Ltd | 10% | P - Purchase | $9.64 | +19,335 | 1,350,000 | +1% | +$186,372 | ||||||
| D | 2025-07-17 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $28.00 | -2,000 | 0 | -100% | -$56,000 | |||||
2025-07-16 | SRRK | Scholar Rock Holding Corp | Flier Jeffrey S. | Dir | S - Sale | $40.02 | -11,136 | 24,070 | -32% | -$445,688 | ||||||
| M | 2025-07-15 | VIR | Vir Biotechnology, Inc. | Eisner Mark | EVP, Chief Medical Officer | S - Sale | $5.47 | -10,382 | 104,618 | -9% | -$56,791 | |||||
2025-07-16 | CRSP | Crispr Therapeutics AG | George Simeon | Dir | P - Purchase | $52.03 | +989,812 | 2,038,763 | +94% | +$51,499,918 | ||||||
| D | 2025-07-15 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $18.66 | -21,000 | 3,762,233 | -1% | -$391,860 | |||||
| M | 2025-07-14 | KRYS | Krystal Biotech, Inc. | Krishnan Suma | Pres, R, D, 10% | S - Sale | $150.39 | -35,873 | 3,086,767 | -1% | -$5,395,001 | |||||
| M | 2025-07-14 | KRYS | Krystal Biotech, Inc. | Krishnan Krish S | Pres, CEO, 10% | S - Sale | $150.39 | -35,873 | 3,086,767 | -1% | -$5,395,001 | |||||
2025-07-08 | BIIB | Biogen Inc. | Izzar Rachid | Head of Global Product Strat. | S - Sale | $135.00 | -2,223 | 6,330 | -26% | -$300,105 | ||||||
2025-07-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $111.03 | -3,000 | 117,168 | -2% | -$333,090 | ||||||
2025-07-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $111.03 | -2,500 | 162,610 | -2% | -$277,575 | ||||||
| D | 2025-07-14 | GILD | Gilead Sciences, Inc. | Bluestone Jeffrey | Dir | S - Sale+OE | $109.74 | -5,000 | 8,920 | -36% | -$548,700 | |||||
2025-07-10 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $34.00 | -191,376 | 3,465,973 | -5% | -$6,506,784 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |